bacteriophage

Phase 3Biologic

AAdaptive Phage Therapeutics, Inc.

bacteriophage is one of 106 biologic programs targeting Pneumonia. It is currently in Phase 3.

Indications

Total Trials

Active Trials

105

Competitors

Pipeline

Status by Indication[3][1]

Indication

PneumoniaNot yet recruiting

Infective EndocarditisRecruiting

Safety and EfficacyActive, not recruiting

Ventilator-Associated PneumoniaActive, not recruiting

ShigellosisActive, not recruiting

PneumoniaPhase 1

Not yet recruiting

Infective EndocarditisPhase 3

Recruiting

Safety and EfficacyPhase 2

Active, not recruiting

Ventilator-Associated PneumoniaPreclinical

Active, not recruiting

ShigellosisPhase 2

Active, not recruiting

Competition

Competitive Landscape

152 competitors in Pneumonia

#DrugCompanyPhaseTrials

bacteriophage

AAdaptive Phage Therapeutics, Inc.

Phase 3

1 2

Jakafi

Incyte

Preclinical

1 3

Primaquine

Sanofi

Preclinical

1 4

Virazole

CConrado Roberto Hoffmann Filho

Preclinical

2 5

Advil

KKenvue Brands

Preclinical

2 6

Retrovir

BBp Consulting, Inc

Preclinical

2 7

Primsol

CConrado Roberto Hoffmann Filho

Preclinical

2 8

Pepcid

KKenvue Brands

Preclinical

1 9

Aciphex

Akero Therapeutics

Preclinical

1 10

Protonix

WWyeth-Lederle Vaccines

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2029

Phase 3Recruiting

Infective Endocarditis

NCT06870409

Q3 2029

Phase 1Not yet recruiting

Pneumonia

NCT07338123

Clinical

Trials by Indication[1]

Safety and Efficacy2 trials

Safety and Efficacy of EcoActive on Intestinal Adherent Invasive E. Coli in Patients With Inactive Crohn's Disease

Active, not recruiting·IIntralytix, Inc.·Phase 1/2·NCT03808103·30 enrolled

A Prospective, Randomized, Double-Blind Controlled Study of WPP-201 for the Safety and Efficacy of Treatment of Venous Leg Ulcers

Completed·SSouthwest Regional Wound Care Center·Phase 1·NCT00663091·64 enrolled

Prosthetic-joint Infection1 trial

Bacteriophage Therapy in Patients With Prosthetic Joint Infections (PJI)

Withdrawn·AAdaptive Phage Therapeutics, Inc.·Phase 2·NCT05269134

Hepatitis1 trial

Safety and Tolerability of NTR-101 in Patients With Acute Alcohol-Associated Hepatitis

Not yet recruiting·NNterica Bio inc·Phase 1·NCT06750588·12 enrolled

Immune Response1 trial

Study of Immune Responses and Safety of Recombinant Human CD40 Ligand in Patients With X-Linked Hyper-IgM Syndrome

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00001145·5 enrolled

Pneumonia1 trial

A Randomized Controlled Trial (RCT) of Yiqi Huoxue Jiedu Formula Combined With Bacteriophages in the Treatment of Severe Pneumonia Caused by Drug-resistant Gram-negative Bacilli

Not yet recruiting·—·Phase 1·NCT07338123·240 enrolled

3 more indications

Infective Endocarditis1 trial

Bacteriophages in Addition to Antibiotics for the Treatment of Patients With Infective Endocarditis

Recruiting·—·Phase 3·NCT06870409·30 enrolled

Shigellosis1 trial

Safety and Efficacy of the Bacteriophage Preparation, ShigActive™, in a Human Experimental Model of Shigellosis

Active, not recruiting·IIntralytix, Inc.·Phase 1/2·NCT05182749·52 enrolled

Ventilator-Associated Pneumonia1 trial

The Effect of Supraglottic and Oropharyngeal Decontamination on the Incidence of Ventilator-associated Pneumonia

Completed·NNorthern State Medical University·N/A·NCT04325685·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 9 trial records for bacteriophage. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — bacteriophage compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for bacteriophage. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Adaptive Phage Therapeutics, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 3[1]
Company: AAdaptive Phage Therapeutics, Inc.

bacteriophage

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2029

Q3 2029

Trials by Indication[1]

Safety and Efficacy2 trials

Prosthetic-joint Infection1 trial

Hepatitis1 trial

Immune Response1 trial

Pneumonia1 trial

Infective Endocarditis1 trial

Shigellosis1 trial

Ventilator-Associated Pneumonia1 trial

References

Drug Info

Quick Facts

Related News